Format

Send to

Choose Destination
Toxicon. 2005 Jun 15;45(8):951-67. Epub 2005 Apr 12.

Snake venoms and coagulopathy.

Author information

1
Toxinology Dept, Women's and Children's Hospital, North Adelaide SA 5006, Australia. toxinaus@wch.sa.gov.au

Abstract

Snakebite affects around 2.5 million humans annually, with greater than 100,000 deaths. Coagulopathy is a significant cause of both morbidity and mortality in these patients, either directly, or indirectly. This paper reviews clinical aspects of snakebite coagulopathy, including types of coagulopathy (procoagulant, fibrinogen clotting, fibrinolytic, platelet-active, anticoagulant, thrombotic, haemorrhagic), diagnosis and treatment. Examples of clinical laboratory findings in selected types of snakebite coagulopathy are presented. Where available, antivenom is the most effective treatment, while standard treatments for other forms of coagulopathy, such as factor replacement therapy and heparin, are either ineffective or dangerous in snakebite coagulopathy, except in specific situations.

PMID:
15922768
DOI:
10.1016/j.toxicon.2005.02.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center